Home -> Law Blog Directory -> Patent Law Blogs -> Patently Obvious
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Patent Law
: Patently ObviousUS Government Asks for Increased Deference When Patent Applicants Challenge BPAI Decisions in Court
By Dennis Crouch
Kappos v. Hyatt (On petition for writ of certiorari, 2011) ?(Download Hyatt.GovtBrief)
Although the US? Patent & Trademark Office (USPTO) and the Department of Justice (DOJ) have been at odds on the issue of the patent eligibility of genetic material isolated from a living organism, the two agencies are speaking with one voice against the Federal Circuit's recent decision in Hyatt v. Kappos. In that en banc opinion, the court broadened a patent applicant's rights associated with the "remedy by civil action" provided by Section 145 of the Patent Act. Under § 145, an applicant can file a civil action in DC District Court whenever "[a]n applicant dissatisfied with the decision of the Board of Patent Appeals and Interferences."
In a 6-2-1 decision, the Federal Circuit reversed its prior precedent and held that a patent applicant is allowed to introduce new evidence in a Section 145 civil action filed to challenge a USPTO refusal to grant patent rights and that the issues implicated by the new facts must be considered de novo.
Judge Moore wrote in the majority opinion that:
[W]e hold that the only limitations on the admissibility of evidence applicable to a § 145 proceeding are the limitations imposed by the Federal Rules of Evidence and Federal Rules of Civil Procedure. Therefore, we hold that the district court applied the wrong legal standard for the admissibility of evidence in a § 145 proceeding and abused its discretion when it excluded Mr. Hyatt's declaration. . . .
The particular significance of a § 145 civil action is that it affords an applicant the opportunity to introduce new evidence after the close of the administrative proceedings?and once an applicant introduces new evidence on an issue, the district court reviews that issue de novo.
However, the Court also held that an applicant may still be barred from presenting new "issues" in the civil action and that, when no new evidence is presented, that BPAI findings and rulings should be given deference under the Administrative Procedures Act.
Petition for Writ of Certiorari: In its petition to the Supreme Court, the US Government argues that the Federal Circuit decision is faulty because it "disregards fundamental principles of administrative law" and diverges from the traditional understanding of the statute.
Getting from the PTO to the Court: After losing at the Board, an applicant has two primary avenues for challenging the Board's decision: (1) Appeal to the Court of Appeals for the Federal Circuit under 35 U.S.C. § 141; or (2) File a civil action in district court under 35 U.S.C. § 145. In Dickinson v. Zurko, the Supreme Court held that Federal Circuit direct review of BPAI decisions under Section 141 must follow the deferential standards that govern judicial review of final agency action under the Administrative Procedure Act (APA). 527 U.S. 150 (1999). In that decision, the Supreme Court distinguished between Section 145 and Section 141 actions ? noting that Section 145 actions "permit the disappointed applicant to present to the court evidence that the applicant did not present to the PTO." However, the court did not address the particular circumstances in which new evidence may be permitted nor did it address how the new evidence should be treated.
Here, the government asks the Supreme Court to fill the gap in Zurko by holding that:
- The plaintiff in a Section 145 action may not introduce new evidence that could have been presented to the PTO in the first place; and
- When new evidence is introduced, the district court should still give deference to the prior decisions of the PTO.
Background: Gilbert Hyatt is a well-known inventor and successful patentee. Hyatt filed a civil action in 2003 after the BPAI sustained written description and enablement rejections for seventy-nine of Hyatt's claims. The examiner had issued "2546 separate rejections of Mr. Hyatt's 117 claims" based on the doctrines of inadequate "written description, lack of enablement, double patenting, anticipation, and obviousness." The Board reversed all of the examiner rejections except for the § 112 p1 arguments. Complicating this case is the fact that the application's claimed priority date is 1975. Hyatt has aggressively pushed the bounds of USPTO practice. This decision is one of more than a dozen Federal Circuit decisions focusing on Hyatt's patent rights. If the Supreme Court takes the case, it will be the second for Hyatt who won a 2002 case against California income tax collectors. In that case, California was pursuing Hyatt for tax revenue for his patent licenses. Hyatt took the case to the Supreme Court and eventually won a $388 million judgment against the state of California for invasion of privacy.
Full post as published by Patently Obvious on April 11, 2011 (boomark / email).
Unconstitutional law to fix unconstitutional law
The New York Times reported on 13 Aug 08:President Bush on Tuesday signed a bill meant to fix a flaw in a 1999 law that has cast doubt on thousands of patent decisions. Under the old law, legal experts said, scores of administrative patent judges were appointed by a government official without the constitutional power to do so...
Eleven easy pieces for obviousness under 103
Patent Docs noted that Bruce Kisliuk (Group Director of Technology Center 1600 (Biotechnology and Organic Chemisry)) stated that TC 1600 examiners were being taught to analyze the issue obviousness using eleven key cases as tools...
Recent Decisions of the Board of Patent Appeals and Interferences Confirm the Need for an Adequate Rational to Modify/Combine
© 2008, Michael E. Kondoudis A colleague passed along the results of a brief survey of some recent Board of Patent Appeals and Interferences (BPAI) decisions in which the BPAI cited KSR and reversed claim rejections...
Court ruling opens possibility of using new evidence in Section 145 patent appeal proceedings
On November 8, 2010, the Federal Circuit issued an opinion in Hyatt v. Kappos that opens the door for patent applicants to introduce new evidence when appealing a Board of Patent Appeals and Interferences (BPAI) affirmance of a final rejection of a patent application...
Consisting Essentially Of
In BPAI decision Ex parte AGARWAL (Appeal No. 2008-2005 / Application No. 11/124,935), Applicants filed a patent application directed to a gold alloy composition. The patent application included independent claim 7 using the transitional phrase "consisting essentially of" as opposed...
Dealing with the EPO's New Excess Claims Fees
By Brad Crawford -- As we previously reported, on December 14, 2007, the Administrative Council of the European Patent Organization increased the amounts of various fees that patent applicants are required to pay...
Unwed Fathers' Rights in Adoption
Landmark Cases in Adoption Law Shape Law with respect to Unwed Fathers
The Paulson Toxic Mortgage Debt Security Act: The Biggest Government Bailout of All Time
Legislative Proprosal for Treasury Authority to Purchase Mortgage-related Assets
Selection of State Supreme Court Judges
How State Court Judges are Selected
Law Enforcement and Criminal Justice Career Choices
Descriptions of law enforcement occupations
California Supreme Court Proposition 8 Decision
Court Rejects Challenges to Proposition 8, but Finds Marriages Valid
Is Barack Obama a Natural Born Citizen?
Wrotnowski v. Bysiewicz (Supreme Court): Does Obama meet the constitutional requirements to be President
Health Insurers
Dictating Medical Decisions
Qui Tam Whistleblower - Government Fraud - Qui Tam Lawsuit
Qui Tam Whistleblower alleging fraud against the government reported by an individual acting as a government whistleblower.
Zantac Patent
GlaxoSmithKline and Cypress Pharmaceutical settle patent infringement dispute.
Soliris Patent
Alexion Pharmaceuticals Inc. agrees to pay the Oklahoma Medical Research Foundation a $10 million patent infringement settlement.
DRAM Patent
ProMOS Technologies and Mosel Vitelic pay MOSAID Technologies an undisclosed patent infringement settlement.
Pollution
50% Increased Risk for Allergy and Asthma from Traffic Fumes










